DK1937221T3 - Depotformulering til pralnacasan - Google Patents

Depotformulering til pralnacasan

Info

Publication number
DK1937221T3
DK1937221T3 DK06805947T DK06805947T DK1937221T3 DK 1937221 T3 DK1937221 T3 DK 1937221T3 DK 06805947 T DK06805947 T DK 06805947T DK 06805947 T DK06805947 T DK 06805947T DK 1937221 T3 DK1937221 T3 DK 1937221T3
Authority
DK
Denmark
Prior art keywords
pralnacasan
depot formulation
type
releases
layer
Prior art date
Application number
DK06805947T
Other languages
English (en)
Inventor
Caren Soennichsen
Roland Wesch
Heiko Meier
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1937221T3 publication Critical patent/DK1937221T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK06805947T 2005-10-08 2006-09-29 Depotformulering til pralnacasan DK1937221T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005048293A DE102005048293A1 (de) 2005-10-08 2005-10-08 Retardformulierung für Pralnacasan
PCT/EP2006/009466 WO2007042160A1 (de) 2005-10-08 2006-09-29 Retardformulierung für pralnacasan

Publications (1)

Publication Number Publication Date
DK1937221T3 true DK1937221T3 (da) 2009-06-15

Family

ID=37764039

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06805947T DK1937221T3 (da) 2005-10-08 2006-09-29 Depotformulering til pralnacasan

Country Status (27)

Country Link
US (1) US8231904B2 (da)
EP (1) EP1937221B1 (da)
JP (1) JP2009511441A (da)
KR (1) KR101362679B1 (da)
CN (1) CN101277683B (da)
AT (1) ATE422354T1 (da)
AU (1) AU2006301573B2 (da)
BR (1) BRPI0617184A2 (da)
CA (1) CA2624838C (da)
CY (1) CY1109131T1 (da)
DE (2) DE102005048293A1 (da)
DK (1) DK1937221T3 (da)
ES (1) ES2322202T3 (da)
HR (1) HRP20090254T1 (da)
IL (1) IL190511A (da)
MA (1) MA29803B1 (da)
ME (1) ME01735B (da)
MY (1) MY146552A (da)
NO (1) NO339360B1 (da)
NZ (1) NZ567268A (da)
PL (1) PL1937221T3 (da)
PT (1) PT1937221E (da)
RS (1) RS50777B (da)
RU (1) RU2419419C2 (da)
SI (1) SI1937221T1 (da)
WO (1) WO2007042160A1 (da)
ZA (1) ZA200802031B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596787C2 (ru) * 2010-07-09 2016-09-10 БиЭйчВи ФАРМА, ИНК. Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
AU2011288413B2 (en) * 2010-08-13 2014-05-22 Mundipharma Pty Limited Use of binders for manufacturing storage stable formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1524526A (zh) * 2003-03-02 2004-09-01 颖 王 尼群地平双层缓释制剂
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
CN1579401A (zh) * 2003-08-11 2005-02-16 李亦武 一种止咳平喘药物新剂型及制备方法
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet

Also Published As

Publication number Publication date
AU2006301573A1 (en) 2007-04-19
US20080279934A1 (en) 2008-11-13
ATE422354T1 (de) 2009-02-15
MY146552A (en) 2012-08-30
RU2419419C2 (ru) 2011-05-27
NZ567268A (en) 2010-08-27
RS50777B (sr) 2010-08-31
EP1937221B1 (de) 2009-02-11
PL1937221T3 (pl) 2009-06-30
KR101362679B1 (ko) 2014-02-13
EP1937221A1 (de) 2008-07-02
DE102005048293A1 (de) 2007-04-12
DE502006002851D1 (de) 2009-03-26
HRP20090254T1 (hr) 2009-06-30
ZA200802031B (en) 2009-08-26
MA29803B1 (fr) 2008-09-01
ES2322202T3 (es) 2009-06-17
RU2008113381A (ru) 2009-10-20
BRPI0617184A2 (pt) 2011-07-12
CN101277683A (zh) 2008-10-01
CA2624838A1 (en) 2007-04-19
ME01735B (me) 2010-08-31
JP2009511441A (ja) 2009-03-19
CN101277683B (zh) 2013-03-20
NO339360B1 (no) 2016-12-05
KR20080054394A (ko) 2008-06-17
SI1937221T1 (sl) 2009-06-30
WO2007042160A1 (de) 2007-04-19
PT1937221E (pt) 2009-04-17
AU2006301573B2 (en) 2013-01-10
CA2624838C (en) 2013-11-19
NO20081896L (no) 2008-04-21
IL190511A0 (en) 2008-11-03
CY1109131T1 (el) 2014-07-02
HK1124531A1 (en) 2009-07-17
US8231904B2 (en) 2012-07-31
IL190511A (en) 2011-05-31

Similar Documents

Publication Publication Date Title
TW200740956A (en) Organic electroluminescent devices
TW200704751A (en) Novel materials for organic electroluminescent devices
BRPI0615347A2 (pt) toleráncia ao estresse em plantas
TW200636046A (en) Novel materials for organic electroluminescent devices
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
ATE553792T1 (de) Medizinische vorrichtungen mit verbundstoffen
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
WO2008057409A3 (en) Sanitizing surfaces
WO2007098203A3 (en) Conductive polymers from precursor polymers, method of making, and use thereof
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
DOP2010000075A (es) Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
CR11397A (es) Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo
NO20081896L (no) Retardformulering for pralnacasan
WO2007136619A3 (en) Solution processible materials and their use in electronic devices
Núñez et al. 81. Tumor maligno en cav idad ca rdíaca simulando trombosis quística
TH22302S1 (th) อิฐบล็อก
TH78104S (th) อิฐบล็อก
TH22295S1 (th) อิฐบล็อก
TH22301S1 (th) อิฐบล็อก
TH22292S1 (th) อิฐบล็อก
TH22303S1 (th) อิฐบล็อก
TH22300S1 (th) อิฐบล็อก
TH78103S (th) อิฐบล็อก
TH22298S1 (th) อิฐบล็อก